SLNSW-Phase 1b/2a study of galunisertib, a small molecu...-TN_cdi_proquest_journals_2442833750

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Full title: Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Author/creator: Wick, Antje, Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana, Cleverly, Ann Louise, Estrem, Shawn T., Wang, Shuaicheng, Lahn, Michael M., Guba, Susan C., Capper, David, Rodon, Jordi.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2442833750

Language: English

Formats: Articles

Publishers: New York: Springer US

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2442833750

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

    Record identifier

    TN_cdi_proquest_journals_2442833750

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2442833750

    Share

    Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2442833750

    Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

    Full title

    Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

    Author / Creator

    Wick, Antje ; Desjardins, Annick ; Suarez, Cristina ; Forsyth, Peter ; Gueorguieva, Ivelina ; Burkholder, Tiana ; Cleverly, Ann Louise ; Estrem, Shawn T. ; Wang, Shuaicheng ; Lahn, Michael M. ; Guba, Susan C. ; Capper, David ; Rodon, Jordi

    Publisher

    New York: Springer US

    Journal title

    Investigational new drugs, 2020, Vol.38 (5), p.1570-1579

    Record Identifier

    TN_cdi_proquest_journals_2442833750

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Anticancer properties Antitumor activity Biomarkers Disease control Dosage Galunisertib Glioblastoma Glioma Growth factors Health services Inhibitors Lymphocytes T Medicine Medicine & Public Health Oncology Patients Pharmacodynamics Pharmacokinetics Pharmacology Pharmacology/Toxicology Phase II Studies Radiochemotherapy Safety Survival T cells Temozolomide Transforming growth factor-b

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2442833750

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2442833750

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections